MicroRNA‑363‑3p inhibits hepatocarcinogenesis by targeting HMGA2 and is associated with liver cancer stage

Wang,Jing; Liang,Huimin; Ge,Haize; Guo,Xinling; Gu,Dongmei; Yuan,Yuhua

doi:10.3892/mmr.2018.9711

MicroRNA‑363‑3p inhibits hepatocarcinogenesis by targeting HMGA2 and is associated with liver cancer stage

Authors:
- Jing Wang
- Huimin Liang
- Haize Ge
- Xinling Guo
- Dongmei Gu
- Yuhua Yuan
View Affiliations

Affiliations: Department of Clinical Laboratory, Tianjin Medical University General Hospital Airport Site, Tianjin 300308, P.R. China, School of Nursing, Tianjin Medical University, Tianjin 300070, P.R. China, Department of Clinical Laboratory, The Third Central Hospital of Tianjin, Tianjin 300170, P.R. China
Published online on: November 29, 2018 https://doi.org/10.3892/mmr.2018.9711
Pages: 935-942
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The importance of microRNAs (miRNAs) in cancer development has been widely recognized in recent decades. In the present study, the function and mechanism of miRNA‑363‑3p (miR‑363‑3p), formerly characterized as a tumor suppressor, in the hepatocarcinogenesis of liver cancer cells was investigated. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was applied to detect the expression of miR‑363‑3p in liver cancer tissues. Cell proliferation, survival and migration capacities were determined by MTT, colony formation and wound‑healing assays, respectively. The targeting of high mobility group AT‑hook 2 (HMGA2) mRNA by miR‑363‑3p was confirmed by bioinformatics analysis, and RT‑qPCR, luciferase reporter and western blot assays. The correlation between the expression levels of HMGA2 and miR‑363‑3p was analyzed. The RT‑qPCR results revealed that the levels of miR‑363‑3p were downregulated in liver cancer tissues. Cellular assays validated that miR‑363‑3p exerted tumor suppressing functions, including the inhibition of cell proliferation, survival and migration abilities in two liver cancer cell lines. Bioinformatics prediction and subsequent experiments demonstrated that HMGA2 was a direct target of miR‑363‑3p. Restoration of the expression of HMGA2 in miR‑363‑3p mimic‑transfected cells reversed the tumor suppressing effects caused by miR‑363‑3p. Finally, there was a significant negative correlation between the expression levels of HMGA2 and miR‑363‑3p in liver cancer tissues. miR‑363‑3p was identified as an important tumor suppressor in liver cancer via targeting HMGA2, which may have potential benefits in liver cancer therapy.

View Figures

View References

1	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–55. 2012. View Article : Google Scholar : PubMed/NCBI
2	Blum HE: Hepatocellular carcinoma: Therapy and prevention. World J Gastroenterol. 11:7391–7400. 2005.PubMed/NCBI
3	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
4	Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
7	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
8	Rapado-González Ó, Majem B, Muinelo-Romay L, Álvarez-Castro A, Santamaría A, Gil-Moreno A, López-López R and Suárez-Cunqueiro MM: Human salivary microRNAs in Cancer. J Cancer. 9:638–649. 2018. View Article : Google Scholar : PubMed/NCBI
9	Hosseinahli N, Aghapour M, Duijf PHG and Baradaran B: Treating cancer with microRNA replacement therapy: A literature review. J Cell Physiol. 233:5574–5588. 2018. View Article : Google Scholar : PubMed/NCBI
10	Ma J and Li X: MicroRNAs are involved in the toxicity of microcystins. Toxin Reviews. 36:165–175. 2017. View Article : Google Scholar
11	Ma J, Li Y, Yao L and Li X: Analysis of microRNA expression profiling involved in MC-LR-induced cytotoxicity by high-throughput sequencing. Toxins (Basel). 9(pii): E232017. View Article : Google Scholar : PubMed/NCBI
12	Chakraborty C, Sharma AR, Sharma G, Sarkar BK and Lee SS: The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. Oncotarget. 9:10164–10174. 2018. View Article : Google Scholar : PubMed/NCBI
13	Vannini I, Fanini F and Fabbri M: Emerging roles of microRNAs in cancer. Curr Opin Genet Dev. 48:128–133. 2018. View Article : Google Scholar : PubMed/NCBI
14	Lou W, Liu J, Gao Y, Zhong G, Chen D, Shen J, Bao C, Xu L, Pan J, Cheng J, et al: MicroRNAs in cancer metastasis and angiogenesis. Oncotarget. 8:115787–115802. 2017. View Article : Google Scholar : PubMed/NCBI
15	Lin Y, Xu T, Zhou S and Cui M: MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1. Oncotarget. 8:101649–101658. 2017. View Article : Google Scholar : PubMed/NCBI
16	Song B, Yan J, Liu C, Zhou H and Zheng Y: Tumor Suppressor Role of miR-363-3p in Gastric Cancer. Med Sci Monit. 21:4074–4080. 2015. View Article : Google Scholar : PubMed/NCBI
17	Ying J, Yu X, Ma C, Zhang Y and Dong J: MicroRNA-363-3p is downregulated in hepatocellular carcinoma and inhibits tumorigenesis by directly targeting specificity protein 1. Mol Med Rep. 16:1603–1611. 2017. View Article : Google Scholar : PubMed/NCBI
18	Wang Y, Chen T, Huang H, Jiang Y, Yang L, Lin Z, He H, Liu T, Wu B, Chen J, et al: miR-363-3p inhibits tumor growth by targeting PCNA in lung adenocarcinoma. Oncotarget. 8:20133–20144. 2017.PubMed/NCBI
19	Hu F, Min J, Cao X, Liu L, Ge Z, Hu J and Li X: MiR-363-3p inhibits the epithelial-to-mesenchymal transition and suppresses metastasis in colorectal cancer by targeting Sox4. Biochem Biophys Res Commun. 474:35–42. 2016. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Han H, Sun D, Li W, Shen H, Zhu Y, Li C, Chen Y, Lu L, Li W, Zhang J, et al: A c-Myc-MicroRNA functional feedback loop affects hepatocarcinogenesis. Hepatology. 57:2378–2389. 2013. View Article : Google Scholar : PubMed/NCBI
22	Gao X, Dai M, Li Q, Wang Z, Lu Y and Song Z: HMGA2 regulates lung cancer proliferation and metastasis. Thorac Cancer. 8:501–510. 2017. View Article : Google Scholar : PubMed/NCBI
23	Huang W, Li J, Guo X, Zhao Y and Yuan X: miR-663a inhibits hepatocellular carcinoma cell proliferation and invasion by targeting HMGA2. Biomed Pharmacother. 81:431–438. 2016. View Article : Google Scholar : PubMed/NCBI
24	Pallante P, Sepe R, Puca F and Fusco A: High mobility group a proteins as tumor markers. Front Med (Lausanne). 2:152015.PubMed/NCBI